A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10489-10494

  Santra, Sampa ^a   Korber, Bette T ^b,c   Muldoon, Mark ^d   Barouch, Dan H ^a   Nabel, Gary J ^e   Gao, Feng ^f   Hahn, Beatrice H ^g   Haynes, Barton F ^f   Letvin, Norman L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c SANTA FE INSTITUTE   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Consensus gene; Cytotoxic T lymphocyte

Indexed keywords

ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; PROTEIN CLADE A; PROTEIN CLADE B; PROTEIN CLADE C; PROTEIN CLADE G; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; EPITOPES; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, ENV; HIV-1; HUMANS; IMMUNE SYSTEM; INTERFERON TYPE II; MACACA MULATTA; PLASMIDS; REGRESSION ANALYSIS; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA;

EID: 48749130188     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0803352105     Document Type: Article

References (24)

1. Gaschen B, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
2. Lin HH, et al. (2006) Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquired Immune Defic Syndr 41:399-404.
3. Arroyo MA, et al. (2006) Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquired Immune Defic Syndr 43:440-445.
4. Gao F, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 groupmconsensus envelope glycoprotein. J Virol 79:1154-1163.
5. Doria-Rose NA, et al. (2005) Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79:11214-11224.
6. Rolland M, et al. (2007) Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 81:8507-8514.
7. Liao HX, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268 -282.
8. Nickle DC, et al. (2007) Coping with viral diversity in HIV vaccine design. PLoS Comput Biol 3:e75.
9. Chakrabarti BK, et al. (2002) Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 76:5357-5368.
10. Li F, et al. (2006) Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 24:6893-6904.
11. Catanzaro AT, et al. (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 16:4085-4092.
12. Seaman MS, et al. (2005) Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 79:2956-2963.
13. Zhan X, et al. (2005) Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 23:5306-5320.
14. Wang S, et al. (2006) Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350:34-47.
15. Pantophlet R, Burton DR (2006) GP120: Target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24:739-769.
16. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
17. Kothe DL, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360:218-234.
18. Kothe DL, et al. (2006) Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352:438-449.
19. Letvin NL, et al. (2004) Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78:7490-7497.
20. Andre S, et al. (1998) Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497-1503.
21. Vogels R, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263-8271.
22. R Development Core Team (2006) R: A Language and Environment for Statistical Computing (R Found for Stat Comput, Vienna, Austria).
23. Crawley MJ (2002) Statistical Computing: An Introduction to Data Analysis Using S-Plus (Wiley, Chichester, UK).
24. Guindon S, Lethiec F, Duroux P, Gascuel O (2005) PHYML Online - A web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res 33:W557-W559.